Stocktoria
Surrozen, Inc./DE SRZN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-23
Chart by TradingView
2/9
Piotroski F — financial health
-15.54
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $3.5M | $10.7M | $0 | $12.5M | $0 |
| Operating income | -$42.1M | -$25.5M | -$45.8M | -$44.3M | -$54.4M |
| Net income | -$242.0M | -$63.6M | -$43.0M | -$36.0M | -$54.6M |
| Operating cash flow | -$30.2M | -$17.6M | -$40.4M | -$44.1M | -$48.8M |
| Free cash flow | -$30.4M | -$17.7M | -$40.8M | -$44.9M | -$50.1M |
| Total assets | $98.7M | $48.5M | $46.1M | $89.4M | $137.2M |
| Total liabilities | $286.5M | $69.8M | $8.1M | $13.4M | $27.5M |
| Shareholders' equity | -$187.8M | -$21.4M | $37.9M | $76.0M | $109.7M |
| Ratios | |||||
| Operating margin | -1210.6% | -239.7% | — | -354.7% | — |
| Net margin | -6960.8% | -596.6% | — | -288.0% | — |
| FCF margin | -873.5% | -165.7% | — | -359.0% | — |
| Return on assets | -245.1% | -131.1% | -93.4% | -40.3% | -39.8% |
| Return on equity | 128.9% | 297.3% | -113.5% | -47.4% | -49.8% |
| Current ratio | 9.22 | 5.32 | 5.75 | 8.35 | 7.75 |
| Revenue growth | -67.4% | — | -100.0% | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 49,126 | $1.4M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -15.54 (distress)
- Working capital / assets 0.827
- Retained earnings / assets -5.341
- EBIT / assets -0.426
- Equity / liabilities -0.655
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001824893 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.